Last week hospitals owned by three big health systems filed suit against CVS Health. The trio filed separately, but all accuse the corporation of robbing them of funds they’re owed through the federal 340B drug pricing program.
The change would represent an imperfect but, in many cases, perfectly appropriate way to oversee the technology without crimping its capabilities. So say three thought leaders who are close watchers of medical ethics and technologies.
